LATEST NEWS

LATEST FINANCIAL RESULTS

Q3 2016

Quarterly Results, Ended Sep 30, 2016      

annualReport-10-k

LATEST 10-K

STOCK INFORMATION

TapImmune Inc.

NSDQ: TPIV

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

TapImmune is developing immunotherapies for a variety of cancers that are designed to target both tumors and metastatic disease. The company’s next-generation technology is designed to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells.

IR CONTACT DETAILS

TapImmune

50 N. Laura St. Suite 2500
Jacksonville, FL 32202
T: 866-359-7541
investor.relations@tapimmune.com